Gagnon Securities LLC Uni Qure N.V. Transaction History

Gagnon Securities LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $96,242 - $144,760	5,668 New	5,668 $106,000
Q3 2020 Nov 12, 2020	SELL	$35.98 - $47.66 $165,292 - $218,950	-4,594 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $170,575 - $342,804	4,594 New	4,594 $329,000
Q3 2019 Nov 08, 2019	SELL	$39.36 - $76.8 $180,819 - $352,819	-4,594 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$27.39 - $68.41 $125,829 - $314,275	4,594 New	4,594 $274,000
Q4 2018 Jan 18, 2019	SELL	$22.8 - $33.93 $126,517 - $188,277	-5,549 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$29.75 - $43.08 $327 - $473	11 Added 0.2%	5,549 $202,000
Q2 2018 Aug 09, 2018	BUY	$21.96 - $39.94 $121,614 - $221,187	5,538 New	5,538 $209,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Gagnon Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gagnon Securities LLC with notifications on news.